Production (Stage)
Atai Life Sciences N.V.
ATAI
$2.33
$0.1155.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 572.56% | -1.91% | -0.90% | 39.48% | 2.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 572.56% | -1.91% | -0.90% | 39.48% | 2.97% |
| Cost of Revenue | -3.49% | -- | -- | -- | -- |
| Gross Profit | 18.06% | -3,578.34% | -3,363.17% | -4,104.43% | -4,171.75% |
| SG&A Expenses | -26.04% | -26.40% | -6.92% | -10.06% | -6.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.87% | -18.29% | -17.54% | -21.32% | -18.80% |
| Operating Income | 15.29% | 18.33% | 17.58% | 21.44% | 18.84% |
| Income Before Tax | -287.07% | -233.45% | -104.57% | 56.60% | 73.81% |
| Income Tax Expenses | 58.46% | 24.00% | -136.19% | -130.35% | -128.38% |
| Earnings from Continuing Operations | -303.94% | -241.83% | -82.35% | 59.78% | 76.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -95.22% | -78.75% | -64.18% | -54.72% | -43.96% |
| Net Income | -340.75% | -271.09% | -92.11% | 59.97% | 77.26% |
| EBIT | 15.29% | 18.33% | 17.58% | 21.44% | 18.84% |
| EBITDA | 15.57% | 18.50% | 17.68% | 21.55% | 18.98% |
| EPS Basic | -332.02% | -263.87% | -89.51% | 61.44% | 77.76% |
| Normalized Basic EPS | -15.13% | -21.15% | -16.81% | -8.72% | 10.45% |
| EPS Diluted | -271.11% | -220.43% | -74.13% | 58.03% | 74.31% |
| Normalized Diluted EPS | -18.14% | -24.40% | -19.76% | -6.39% | 12.72% |
| Average Basic Shares Outstanding | 4.56% | 2.30% | 2.02% | 1.12% | 0.68% |
| Average Diluted Shares Outstanding | 1.06% | -1.14% | -1.41% | 4.59% | 4.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |